World Health Organization (2020) Obesity and overweight [Internet]. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 8 Nov 2022

Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT et al (2014) American society of clinical oncology position statement on obesity and cancer. J Clin Oncol 32:3568–3574

Article  PubMed  PubMed Central  Google Scholar 

Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD et al (2021) Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol 39:2037–2048

Article  PubMed  Google Scholar 

Smit C, De Hoogd S, Brüggemann RJM, Knibbe CAJ (2018) Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol 14:275–85

Article  CAS  PubMed  Google Scholar 

Desar IME, Burger DM, van Hoesel QGCM, Beijnen JH, van Herpen CML, van der Graaf WTA (2009) Pharmacokinetics of sunitinib in an obese patient with a GIST. Ann Oncol Off J Eur Soc Med Oncol 20:599–600

Article  CAS  Google Scholar 

Lankheet NAG, Kloth JSL, Gadellaa-Van Hooijdonk CGM, Cirkel GA, Mathijssen RHJ, Lolkema MPJK et al (2014) Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer 110:2441–2449

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27:3141–3147

Article  CAS  PubMed  Google Scholar 

Groenland SL, van Nuland M, Verheijen RB, Schellens JHM, Beijnen JH, Huitema ADR et al (2019) Therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Clin Pharmacokinet 58:299–308

Article  CAS  PubMed  Google Scholar 

Groenland SL, Geel DR, Janssen JM, de Vries N, Rosing H, Beijnen JH et al (2021) Exposure-response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non-small cell lung cancer patients. Clin Pharmacol Ther 109:394–402

Article  CAS  PubMed  Google Scholar 

Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A et al (2017) Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer 72:54–61

Article  CAS  PubMed  Google Scholar 

Verheijen RB, Bins S, Mathijssen RHJ, Lolkema MP, Van Doorn L, Schellens JHM et al (2016) Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin Cancer Res 22:5738–5746

Article  CAS  PubMed  Google Scholar 

European Medicines Agency Committee for Medicinal Products For Human Use (CHMP). Abiraterone Accord, INN-abiraterone acetate. https://www.ema.europa.eu/en/documents/product-information/abiraterone-accord-epar-product-information_en.pdf. Accessed 23 Sep 2023

European Medicines Agency Committee for Medicinal Products For Human Use (CHMP). Alecensa, INN-alectinib. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Accessed 23 Sep 2023

European Medicines Agency Committee for Medicinal Products For Human Use (CHMP). Cometriq, INN-cabozantinib. https://www.ema.europa.eu/en/documents/product-information/cometriq-epar-product-information_en.pdf. Accessed 23 Sep 2023

European Medicines Agency Committee for Medicinal Products For Human Use (CHMP). Xalkori, INN-crizotinib. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Accessed 23 Sep 2023

European Medicines Agency Committee for Medicinal Products For Human Use (CHMP). Imatinib Teva-INN-imatinib. https://www.ema.europa.eu/en/documents/product-information/imatinib-teva-epar-product-information_en.pdf. Accessed 23 Sep 2023

European Medicines Agency Committee for Medicinal Products For Human Use (CHMP). Votrient, INN-pazopanib. https://www.ema.europa.eu/en/documents/product-information/votrient-epar-product-information_en.pdf. Accessed 23 Sep 2023

European Medicines Agency Committee for Medicinal Products For Human Use (CHMP). Sunitinib Accord, INN-sunitinib. https://www.ema.europa.eu/en/documents/product-information/sunitinib-accord-epar-product-information_en.pdf. Accessed 23 Sep 2023

European Medicines Agency Committee for Medicinal Products For Human Use (CHMP). Mekinist, INN-trametinib. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Accessed 23 Sep 2023

Lacy S, Nielsen J, Yang B, Miles D, Nguyen L, Hutmacher M (2018) Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. Cancer Chemother Pharmacol 81:1061–1070

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35

Article  CAS  PubMed  Google Scholar 

van Nuland M, Groenland S, Bergman A, Steeghs N, Rosing H, Venekamp N et al (2020) Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 23:244–251

Article  PubMed  Google Scholar 

van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, Versluis J, Huitema ADR, Koolen SLW et al (2023) Therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacokinet 62(10):1333–1364

Article  PubMed  PubMed Central  Google Scholar 

Van Nuland M, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH (2017) Development and validation of an LC-MS/MS method for the simultaneous quantification of abiraterone, enzalutamide, and their major metabolites in human plasma. Ther Drug Monit 39:243–251

Article  PubMed  Google Scholar 

Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM et al (2018) Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs. Biomed Chromatogr 32:e4147

Article  Google Scholar 

Janssen JM, de Vries N, Venekamp N, Rosing H, Huitema ADR, Beijnen JH (2019) Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma. J Pharm Biomed Anal 174:561–566

Article  CAS  PubMed  Google Scholar 

Lankheet NAG, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH, Huitema ADR (2013) Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 27:466–476

Article  CAS  PubMed  Google Scholar 

Verheijen RB, Thijssen B, Rosing H, Schellens JHM, Nan L, Venekamp N et al (2018) Fast and straightforward method for the quantification of pazopanib in human plasma using LC-MS/MS. Ther Drug Monit 40:230–236

Article  CAS  PubMed  Google Scholar 

Janssen JM, Dorlo TPC, Beijnen JH, Huitema ADR (2020) Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs. Ther Drug Monit 42:532–539

Article  PubMed  Google Scholar 

Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I et al (2005) Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 60:35–44

Article  CAS  PubMed  PubMed Central  Google Scholar 

Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M et al (2009) Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol 63:229–238

Article  CAS  PubMed  Google Scholar 

Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D et al (2016) Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol 77:807–817

Article  CAS  PubMed  Google Scholar 

Gibson EG, Campagne O, Selvo NS, Gajjar A, Stewart CF (2021) Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. Cancer Chemother Pharmacol 88:1009–1020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang E, DuBois SG, Wetmore C, Khosravan R (2020) Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors. Cancer Chemother Pharmacol 86:181

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chi KN, Spratlin J, Kollmannsberger C, North S, Pankras C, Gonzalez M et al (2015) Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol 55:1406–1414

Article  CAS  PubMed  Google Scholar 

Morcos PN, Guerini E, Parrott N, Dall G, Blotner S, Bogman K et al (2017) Effect of food and esomeprazole on the pharmacokinetics of alectinib, a highly selective alk inhibitor, in healthy subjects. Clin Pharmacol Drug Dev 6:388–397

Article  CAS  PubMed  Google Scholar 

Yu H, van Erp N, Bins S, Mathijssen RHJ, Schellens JHM, Beijnen JH et al (2017) Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet 56:293–303

Article  CAS  PubMed  Google Scholar 

Delbaldo C, Chatelut E, Ré M, Deroussent A, Séronie-Vivien S, Jambu A et al (2006) Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12:6073–6078

Article  CAS  PubMed  Google Scholar 

Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnke T et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022–4028

Article  CAS  PubMed  Google Scholar 

Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I et al (2012) Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. Haematologica 97:731–738

Article  CAS  PubMed